The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
Open accessAbstract
BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even among omega‐3 fatty acid studies, there are marked differences with respect to the relatively low doses of omega‐3 administered and the ratio of EPA to DHA.16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ORIGIN trial, which enrolled more than 12,000 patients with impaired fasting glucose and at high risk for cardiovascular events, the administration of 1 g/day of combined EPA + DHA (465 mg of EPA and 375 mg of DHA) had no impact on cardiovascular mortality [89].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, many previous 20 , 21 , 22 , 23 and recently completed clinical studies 24 , 25 showed that ω3 PUFA supplementation did not offer significant favorable impacts on cardiovascular events.”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“but subsequent larger trials failed to replicate these findings. 8,9”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the dosage used in OMEMI was about twice that used in comparable earlier trials 5, 7, 23, 30 , although considerably lower than the dosage used in REDUCE-IT 14 , and also in the STRENGTH trial 36 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Other more recent omega‐3 therapy outcome studies conducted in the presence of statins have been less encouraging, but these studies were characterized by evaluating nonhypertriglyceridemic patient populations (eg, TG <200 mg/dL) and administering low doses of long‐chain omega‐3 fatty acids (eg, eicosapentaenoic acid [EPA] and/or docosoahexaenoic acid [DHA]).19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Our initial manuscript included Trials such as ORIGIN8, ASCEND9, Alpha Omega10, and JELIS5; among these trials, only one trial had IPE, and the rest of the trials had a combination of EPA and DHA, so our results were skewed as search strategy missed significant studies.”
From Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials (2024) · cites this paper as [8]
In the citing paper
“Data from studies on supplementation with n-3 fatty acids do not support recommending n-3 fatty acid supplements for secondary prevention of CVD in T2DM.86,87”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“In the ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial, 12 537 patients (mean age 63.5 years) at high CVD risk with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or T2DM were randomized to insulin glargine titrated to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86 After a median follow-up of 6.2 years, the incidence of CV”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“The JELIS study692) conducted in Japan found that the addition of EPA to statins showed a significant preventive effect on major cardiovascular events compared to statin monotherapy.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [692]
In the citing paper
“Evidence does not conclusively support recommending n-3 (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) supplements for all people with diabetes for the prevention or treatment of cardiovascular events (70,209,210).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176158 · Cited by 2,705
(1999) · PubMed · Cited by 2,062
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Self-citationGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.287.14.1815 · Cited by 1,018
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored
Calder, P. C. (2004) · Clinical Science · doi:10.1042/cs20040119 · Cited by 571
Cardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 513
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 601–700 of 933
The Rise and Fall “ing” of the HDL Hypothesis
Feghaly, J., & Mooradian, A. D. (2020) · Drugs · doi:10.1007/s40265-020-01265-4 · Cited by 8
Arsenyadis, F., Ahmad, E., Redman, E., Yates, T. E., Davies, M. J., & Khunti, K. (2022) · Nutrients · doi:10.3390/nu14091827 · Cited by 8
de la Fuente, R. L., Naesgaard, P. A., Nilsen, S. T., Woie, L., Aarsland, T., Gundersen, T. E., & Nilsen, D. W. T. (2012) · Scandinavian Cardiovascular Journal · doi:10.3109/14017431.2012.747220 · Cited by 8
Li, Y., Jia, Z., & Zhu, H. (2019) · doi:10.20455/ros.2019.817 · Cited by 8
Picard, F. A., & Steg, P. G. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00919-2 · Cited by 8
Diet and cardiovascular disease: Dietary patterns, foods and nutrients
Clifton, P. M., & Tapsell, L. C. (2013) · Nutrition & Dietetics · doi:10.1111/1747-0080.12069 · Cited by 8
The role of fatty acids from fish in the prevention of stroke
de Goede, J., & Geleijnse, J. M. (2012) · BMJ · doi:10.1136/bmj.e7219 · Cited by 8
Tatsuno, I. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.971756 · Cited by 7
Fish Oil Supplementation Modifies the Genetic Potential for Blood Lipids
Sun, Y., McDonald, T., Baur, A., Xu, H., Bateman, N., Shen, Y., Li, C., & Ye, K. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.07.009 · Cited by 7
Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies
Goyal, P., Igel, L. I., LaScalea, K., & Borden, W. B. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0390-0 · Cited by 7
Lu, L. W., Quek, S. Y., Lu, S.-P., & Chen, J. (2023) · Metabolites · doi:10.3390/metabo13050630 · Cited by 7
Gupta, A., & Alkhalil, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113758 · Cited by 7
Liu, X., Li, Y., Wan, X., Zhuang, P., Wu, Y., Zhang, L., Yang, A., Yao, J., Zhang, Y., & Jiao, J. (2023) · Nutrients · doi:10.3390/nu15143176 · Cited by 7
Emerging approaches for the treatment of hypertriglyceridemia
Rizzo, M., Pérez‐Martínez, P., Nikolić, D., Montalto, G., & López‐Miranda, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.823402 · Cited by 7
Mizia‐Stec, K., Mizia, M., Haberka, M., Lasota, B., Gieszczyk-Strózik, K., Chmiel, A., Najda, J., Gąsior, Z., & Kyrcz‐Krzemień, S. (2013) · Cardiology Journal · doi:10.5603/cj.2013.0132 · Cited by 7
The past, present and future of lipidlowering therapy
Najam, O., Lambert, G. C., & Ray, K. K. (2015) · Clinical Lipidology · doi:10.2217/clp.15.40 · Cited by 7
Shimada, T., Kadota, K., Eguchi, H., Osakada, K., Kuwayama, A., Ohya, M., Miura, K., Amano, H., Kubo, S., Ozaki, M., et al. (2017) · International Heart Journal · doi:10.1536/ihj.16-565 · Cited by 7
Optimal Dose of n-3 Polyunsaturated Fatty Acids for Cardiovascular Event Prevention
Nishizaki, Y., & Daida, H. (2020) · Circulation Reports · doi:10.1253/circrep.cr-20-0012 · Cited by 7
Yokote, K., Niwa, K., Hakoda, T., Oh, F., Kajimoto, Y., Fukui, T., Kim, H., Noda, Y., Lundström, T., & Yajima, T. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-0358 · Cited by 7
The return of triglycerides and revival of omega-3 fatty acids!
Ferrières, J. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.04.004 · Cited by 7
Effects of polyunsaturated fatty acid–rich diets and risk of non-communicable diseases
Singh, R. B., Watanabe, S., Li, D., Nakamura, T., Juneja, L. R., Takahashi, T., Wichansawakun, S., Wilczyńska, A., Jantan, I., Sulaeman, A., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819815-5.00011-2 · Cited by 7
Hall, W. L. (2024) · Proceedings of The Nutrition Society · doi:10.1017/s0029665124000181 · Cited by 7
n-3 Fatty acids and cardiovascular disease: the story is not over yet
Bilato, C. (2013) · Aging Clinical and Experimental Research · doi:10.1007/s40520-013-0077-y · Cited by 7
Namazi, G., Asa, P., Movahedian, A., Sarrafzadegan, N., Sadeghi, M., & Pourfarzam, M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.03.011 · Cited by 7
Philip, S., Chowdhury, S., Nelson, J. R., Everett, P. B., Hulme-Lowe, C. K., & Schmier, J. K. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1207652 · Cited by 7
Leshno, M., Goldbourt, U., Pinchuk, I., & Lichtenberg, D. A. (2017) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2017.1402868 · Cited by 7
Clasificación de los desenlaces en los ensayos clínicos
Tabares, D. H., Carrillo, V. P., & Gómez, J. R. M. (2019) · Medicina UPB · doi:10.18566/medupb.v38n2.a07 · Cited by 7
Qi, Y., Li, Y., Wang, Z., Wang, X., Meng, H., Li, W., Chen, D.-C., Li, M., Liu, J., & An, S. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00626-7 · Cited by 7
Calder, P. C., & Deckelbaum, R. J. (2019) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000543 · Cited by 7
Abuknesha, N. R., O’Keefe, J. H., Qian, F., Tintle, N., Lin, Y., Sun, Y., Qian, H., Aisen, P. S. S., Albert, C. M., Aronson, W. J., et al. (2026) · Proceedings of The Nutrition Society · doi:10.1017/s0029665126102493 · Cited by 6
Nandoskar, S. D., Rana, S., & Singh, S. K. (2026) · Archives of Microbiology · doi:10.1007/s00203-025-04708-2 · Cited by 6
Zhang, T., Li, G., Duan, M., Lv, T., Feng, D., Lü, N., Zhou, Y., Gu, L., Zhu, W., & Gong, J. (2021) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2269 · Cited by 6
Cao, M., Yang, F., Guo, Y., Liu, R., Chang, M., Wang, Y., Wei, W., Jin, Q., & Wang, X. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104066 · Cited by 6
Amedei, A., Lamminpää, I., & Parolini, C. (2025) · Biomedicines · doi:10.3390/biomedicines13102428 · Cited by 6
Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia
Jacobson, T. A. (2014) · Clinical Lipidology · doi:10.2217/clp.14.10 · Cited by 6
Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTIDUDE, FAME II and more
Ukena, C., Böhm, M., & Schirmer, S. H. (2012) · Clinical Research in Cardiology · doi:10.1007/s00392-012-0511-8 · Cited by 6
Hussain, A., Rifai, M. A., Mahtta, D., Liu, J., Jain, V., & Virani, S. S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00900-5 · Cited by 6
Marine-derived n-3 fatty acids therapy for stroke
Campano, C. G. A., MacLeod, M. J., Aucott, L. S., & Thiès, F. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012815.pub3 · Cited by 6
ω‑3 fatty acids in atherosclerotic cardiovascular disease (Review)
Xie, X., Liu, X., Li, R., Ling, F., & Huang, F. (2024) · Biomedical Reports · doi:10.3892/br.2024.1782 · Cited by 6
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 6
Jain, R. K., & Laiteerapong, N. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0665-7 · Cited by 6
Bjerregaard, P. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.10.071 · Cited by 6
Critical review of non-statin treatments for dyslipoproteinemia
Pang, J., Chan, D. C., & Watts, G. F. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.888312 · Cited by 6
Creating the Future of Evidence-Based Nutrition Recommendations: Case Studies from Lipid Research
Dwyer, J. T., Rubin, K. H., Fritsche, K. L., Psota, T., Liska, D. J., Harris, W. S., Montain, S. J., & Lyle, B. J. (2016) · Advances in Nutrition · doi:10.3945/an.115.010926 · Cited by 6
Birkeland, K. I., Grill, V., Wium, C., McQueen, M., López-Jaramillo, P. A., Lee, S. F., & Gerstein, H. C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13528 · Cited by 6
Big Fish or No Fish; Eicosapentaenoic Acid and Cardiovascular Disease
Goldberg, I. J., Gjini, J., & Fisher, E. A. A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.012 · Cited by 6
Gut Microbiota and Nutrition: Strategies for the Prevention and Treatment of Type 2 Diabetes
Sastre, M., Cimbalo, A., Mañes, J., & Manyes, L. (2024) · Journal of Medicinal Food · doi:10.1089/jmf.2022.0154 · Cited by 6
Kubo, M., Miyoshi, T., Kimura, T., Noda, Y., Kohno, K., Nakamura, K., Morita, H., & Ito, H. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0082-3 · Cited by 6
Halcox, J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.16 · Cited by 6
AlSaleh, A. F. F., Maniou, Z., Lewis, F. J., Hall, W. L., Sanders, T. A. B., & O’Dell, S. D. (2014) · Genes & Nutrition · doi:10.1007/s12263-014-0412-8 · Cited by 6
Nutritional Management of Diabetes—A Critical Review
Chaubey, P., Suvarna, V., Sangave, P. C., & Singh, A. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813822-9.00019-9 · Cited by 6
Dagenais, G. R., Jung, H. J., Bogaty, P. M., Bosch, J., Yusuf, S., & Gerstein, H. C. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13674 · Cited by 6
Syamsunarno, M. R. A. A., Agustin, D. F., Anggraeni, N., & Kania, N. (2020) · Indonesian Journal of Clinical Pharmacy · doi:10.15416/ijcp.2020.9.2.137 · Cited by 6
Abdissa, D. (2021) · Nutrition and Dietary Supplements · doi:10.2147/nds.s298870 · Cited by 6
n–3 Fatty Acids and Cardiovascular Outcomes in Dysglycemia
Hurtado‐Torres, G. F., & Sandoval-Munro, R. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1210552 · Cited by 6
Is There Something Fishy About Fish Oil?
Šunderić, M., Robajac, D., Gligorijević, N., Miljuš, G., Nedić, O., Smilkov, K., Ackova, D. G., Rudić-Grujić, V., & Penezić, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190705185800 · Cited by 5
Long-chain omega-3 fatty acids and cardiovascular health
Kuratko, C. N., Nolan, C., & Salem, N. (2014) · Nutrafoods · doi:10.1007/s13749-014-0020-7 · Cited by 5
Agreement Between Mega-Trials and Smaller Trials
Kastrati, L., Raeisi‐Dehkordi, H., Llanaj, E., Quezada‐Pinedo, H. G., Khatami, F., Ahanchi, N. S., Llane, A., Meçani, R., Muka, T., & Ioannidis, J. P. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.32296 · Cited by 5
Bozack, A. K., Khodasevich, D., Nwanaji‐Enwerem, J. C., Gladish, N., Shen, H., Daredia, S., Needham, B. L., Rehkopf, D. H., Guasch‐Ferré, M., & Cárdenas, A. (2025) · npj Aging · doi:10.1038/s41514-025-00298-x · Cited by 5
Emerging drugs for hyperlipidaemia: an update
Florentin, M., Kostapanos, M. S., Kei, A. A., & Elisaf, M. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.976553 · Cited by 5
Goals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes for Both
Perreault, L. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0316 · Cited by 5
Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 2.
Lucius, K., & Trukova, K. (2015) · PubMed Central · Cited by 5
Permpanich, A., Kulsomboon, V., & Udol, K. (2015) · Asian Biomedicine · doi:10.5372/1905-7415.0901.364 · Cited by 5
Statins: An Update on Clinical Issues and Selected Adverse Effects
Gulum, A. H., & Hume, A. L. (2015) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2014.09.004 · Cited by 5
Balogun, K. A., & Cheema, S. K. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_27 · Cited by 5
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Kim, M. S., Kim, J., Lee, S. G., Jung, E.-J., Lee, S. H., Huang, W. Y., Han, B. K., Jung, D. E., Yang, S. B., Ji, I., et al. (2023) · Healthcare · doi:10.3390/healthcare11162365 · Cited by 5
Do Omega-3 Fatty Acids Have a Role in Prevention of Cardiovascular Disease?
Barringer, T. A. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00395 · Cited by 5
Glickman-Simon, R., & Ehrlich, A. M. (2013) · EXPLORE · doi:10.1016/j.explore.2012.11.006 · Cited by 5
Chan, D. C., Pang, J., & Watts, G. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_30-1 · Cited by 5
Explaining the Recent Fish Oil Trial “Failures”
Niazi, J. J. D. A. K. (2013) · Journal of Glycomics & Lipidomics · doi:10.4172/2153-0637.1000e112 · Cited by 5
Wang, C., Wang, F., Cao, Q., Li, Z., Huang, L., & Chen, S. (2018) · Aging Medicine · doi:10.1002/agm2.12032 · Cited by 5
Behera, S. S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191112141320 · Cited by 5
A case-based approach to integrative medicine for cardiovascular disease prevention
Slostad, B. D., Khalsa, T., Young, K. M., Guerra, H., & Bhagra, A. (2019) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2019.12.001 · Cited by 5
Effects of dietary n-3 polyunsaturated fatty acids on cardiovascular disease
Yamagata, K. (2020) · Studies in natural products chemistry · doi:10.1016/b978-0-12-817903-1.00007-3 · Cited by 5
Arnesen, H., Myhre, P. L., & Seljeflot, I. (2020) · Nutrients · doi:10.3390/nu12103014 · Cited by 5
Wijkman, M. O., Claggett, B. L., Pfeffer, M. A., Paré, G., McQueen, M., Hess, S., Lee, S. F., & Gerstein, H. C. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107928 · Cited by 5
Niwa, K., Tanaka, A., Funakubo, H., Otsuka, S., Yoshioka, N., Kudo, N., Tobe, A., Sakakibara, K., Miki, Y., Kataoka, T., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.7336-21 · Cited by 5
Pedro‐Botet, J., Barrios, V., Sánchez‐Margalet, V., Tamargo, J. L., Arrieta, F., Gámez, J. M., Gimeno-Orna, J. A., Escobar, C., Gómez‐Doblas, J. J., & Pérez, A. (2022) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2022.03.004 · Cited by 5
Role of Dyslipidemia in Patients With Chronic Kidney Disease
Marino, A., & Tannock, L. R. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2676 · Cited by 5
Colorectal Cancer Prevention and Fishful Thinking
Umar, A., Richmond, E. S., & Kramer, B. S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv052 · Cited by 5
Professional Practice Committee
Aiello, L. P., Colberg, S. R., Condon, J. E., Coustan, D. R., Inzucchi, S. E., King, G. L., Kuo, S., Lamster, I. B., Maynard, G., Morton-Eggleston, E., et al. (2015) · Diabetes Care · doi:10.2337/dc16-s002 · Cited by 5
Elian, V., Dorita, A., Stegaru, D., & Vinereanu, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178558 · Cited by 4
Fish oil for prevention of sudden death in hemodialysis patients?
Teta, D. (2013) · Kidney International · doi:10.1038/ki.2013.54 · Cited by 4
Hermans, M. P., Bouénizabila, E., Amoussou-Guénou, D., Ahn, S. A., & Rousseau, M. F. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0226-z · Cited by 4
Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment – a clinical appraisal
Vora, J. P., Ray, K. K., Kosiborod, M., Poulter, N. R., Rajagopalan, S., & Leiter, L. A. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.06.003 · Cited by 4
Sabbour, H. M., Bhatt, D. L., Elhenawi, Y., Aljaberi, A. K., Bennani, L., Fiad, T. M., Hasan, K. Y., Hashmani, S., Hijazi, R. A., Khan, Z., et al. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07519-z · Cited by 4
Hamaya, R., Cook, N. R., Sesso, H. D., Buring, J. E., & Manson, J. E. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.02.028 · Cited by 4
Diabetic Dyslipidemia - Role of Saroglitazar
Majumder, A. (2014) · Medicinal Chemistry · doi:10.4172/2161-0444.1000212 · Cited by 4
Diabetic Dyslipidemia and Risk of Cardiovascular Disease
Viljoen, A., Joshi, S., & Wierzbicki, A. S. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch43 · Cited by 4
Kłosiewicz−Latoszek, L., Cybulska, B., & Tyszko, P. Z. (2020) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/126674 · Cited by 4
Omega-3 fatty acids for intermittent claudication
Mohammady, M., Brown, T. J., Radmehr, M., Shamsoddin, E., & Janani, L. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003833.pub5 · Cited by 4
Ernährungstherapie des Typ-2-Diabetes
Hauner, H. (2013) · Der Diabetologe · doi:10.1007/s11428-013-1085-4 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 4
Fat‐1 expression alleviates atherosclerosis in transgenic rabbits
Zhang, C., Wang, X., Sun, S., Fu, Y., Wu, Y., Zhao, S., Fan, X., & Liu, E. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17188 · Cited by 4
Takeda, Y., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., & Sakurai, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061360 · Cited by 4
Dietary Patterns and Insulin Resistance
Torsoni, A. S., Milanski, M., & Torsoni, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801585-8.00002-6 · Cited by 4
A state profile of IT sophistication in nursing homes.
Alexander, G. L. (2008) · PubMed Central · Cited by 4
Serhiyenko, V. A., Serhiyenko, A. A., & Sehin, V. B. (2014) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.2478/rjdnmd-2014-0014 · Cited by 4
Metadata
- Authors
- The ORIGIN Trial Investigators
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 309-318
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1560062315
- Semantic Scholar
- 00cc8344ced92b3c8921b97df8607e6b3032e111
- Cited by
- 929
- References
- 21
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 41 · 2023: 53 · 2022: 51 · 2021: 57 · 2020: 76 · 2019: 60 · 2018: 72 · 2017: 56 · 2016: 90 · 2015: 79 · 2014: 90 · 2013: 122 · 2012: 38
- FWCI
- 97.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- omega-3 fatty acids, cardiovascular outcomes, type 2 diabetes, dysglycemia, impaired fasting glucose, impaired glucose tolerance, insulin glargine, cardiovascular mortality, major vascular events, triglycerides, serum lipids, cardiac arrhythmias, cardiovascular risk reduction, dietary supplementation, omega-3 fatty acid ethyl esters
- MeSH terms
- Insulin Glargine, Aged, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Treatment Failure, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
